Faeth Therapeutics' (FTH) readout for its PIK-201 phase 2 clinical trial evaluating PIKTOR in endometrial cancer, scheduled in Q4, should be a major inflection point for the company, Oppenheimer said in a Tuesday note.

The summary of topline data from the trial is expected by year-end 2026, with evaluations of about 40 patients in endometrial cancer, the brokerage said. Notable data includes overall response rate, landmark survival analyses, and safety profile, Oppenheimer added.

PIKTOR may have a bigger opportunity in breast cancer, Oppenheimer said, but added it has a "meaningful market opportunity" in endometrial cancer, which analysts called the "right place" to establish proof of concept.

Oppenheimer has an outperform rating and $60 price target on Faeth Therapeutics.

Price: 26.09, Change: -0.80, Percent Change: -2.98